Celularity Enters Strategic Partnership, Expected Transaction Value Up to $35 Million
Celularity announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions. The transaction is intended to monetize Celularity's commercial biomaterials portfolio while allowing the Company to concentrate resources on advancing its longevity-focused therapeutic pipeline. Under the terms of the agreements, Celularity granted an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs. The Company expects to receive upfront consideration at closing and may receive additional milestone-based payments totaling up to $35 million, representing non-dilutive capital. Celularity will also be eligible to receive royalties on future net sales of certain development-stage products upon commercialization.
Trade with 70% Backtested Accuracy
Analyst Views on CELU
About CELU
About the author
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
